 |
3 Products |  |
9 Diseases | | 3 Products |
|
3 Trials |  |
74 News |  |
| 12» |
- || Veozah (fezolinetant) / Astellas, osanetant (ACER-801) / Sanofi, Zevra Therap, elinzanetant (NT-814) / Bayer
Review, Journal: Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause. (Pubmed Central) - Mar 25, 2024
Because of the high-quality evidence supporting the efficacy of fezolinetant and elinzanetant, these agents may be an effective option with mild adverse events for women seeking nonhormone treatment of VMS.
- | osanetant (ACER-801) / Sanofi, Zevra Therap
Enrollment change, Trial completion date, Trial withdrawal: POSH-MAP: Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate (clinicaltrials.gov) - Feb 21, 2024
P1, N=0, Withdrawn, Sponsor: University of Kansas Medical Center
Because of the high-quality evidence supporting the efficacy of fezolinetant and elinzanetant, these agents may be an effective option with mild adverse events for women seeking nonhormone treatment of VMS. N=10 --> 0 | Trial completion date: Nov 2025 --> Oct 2023 | Recruiting --> Withdrawn
- | Edsivo (celiprolol) / Zevra Therap
Journal: Despite celiprolol therapy, patients with vascular Ehlers-Danlos syndrome remain at risk of vascular events: A 12-year experience in an Italian referral center. (Pubmed Central) - Dec 16, 2023
Nonetheless, the risk of symptomatic vascular events remained nonnegligible. Future studies should identify reliable predictors of major adverse events and explore additional therapeutic strategies that could further lower the risk of life-threatening events in this population.
- | osanetant (ACER-801) / Sanofi, Acer Therap
Journal: Activation of neurokinin-III receptors modulates human atrial TASK-1 currents. (Pubmed Central) - Nov 27, 2023
Heterologously expressed human TASK-1 channels are inhibited by neurokinin-III receptor activation in a DAG dependent fashion. Patch-clamp measurements, performed on human atrial cardiomyocytes suggest that the atrial-specific effects of neurokinin-III receptor activation on cardiac excitability are predominantly mediated via TASK-1 currents.
- | Edsivo (celiprolol) / Acer Therap
Biomarker, Clinical, Clinical guideline, Retrospective data, Review, Clinical Trial,Phase II, Journal: Celiprolol and sympatho-immune interface in COVID-19. (Pubmed Central) - Nov 6, 2023
Patch-clamp measurements, performed on human atrial cardiomyocytes suggest that the atrial-specific effects of neurokinin-III receptor activation on cardiac excitability are predominantly mediated via TASK-1 currents. No abstract available
- | Edsivo (celiprolol) / Acer Therap
Journal: Bisoprolol versus celiprolol on dynamic hyperinflation, cardiopulmonary exercise and domiciliary safety in COPD: a single-centre, randomised, crossover study. (Pubmed Central) - Jul 19, 2023
P4
A broad spectrum of other non-invasive cardiopulmonary and domiciliary safety outcomes was equally reassuring. Bronchoprotection with a concomitant long-acting muscarinic antagonist might be an important safety measure in this context.
- | Edsivo (celiprolol) / Acer Therap
Journal, HEOR: Improvement in Quality of Life Following Celiprolol Hydrochloride Administration in a Patient with Vascular Ehlers-Danlos Syndrome: A Case Report. (Pubmed Central) - Jun 26, 2023
Vascular Ehlers-Danlos syndrome requires specialized treatment that is scientifically proven to prevent a major vascular event. Proactive genetic diagnosis is recommended in patients suspected of having vascular Ehlers-Danlos syndrome after careful patient interview.
- Edsivo (celiprolol) / Acer Therap
Medical Treatment Of Patients With Vascular Ehlers Danlos Syndrome: How Does Celiprolol Treatment Work And How Does It Help (Grand Ballroom West, 3rd Floor) - May 7, 2023 - Abstract #VEITH2023VEITH_1017;
- || osanetant (ACER-801) / Sanofi, Acer Therap
Trial completion: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause (clinicaltrials.gov) - Apr 4, 2023
P2a, N=49, Completed, Sponsor: Acer Therapeutics Inc.
Proactive genetic diagnosis is recommended in patients suspected of having vascular Ehlers-Danlos syndrome after careful patient interview. Active, not recruiting --> Completed
- || osanetant (ACER-801) / Sanofi, Acer Therap
Enrollment closed: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause (clinicaltrials.gov) - Mar 17, 2023
P2a, N=56, Active, not recruiting, Sponsor: Acer Therapeutics Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || osanetant (ACER-801) / Sanofi, Acer Therap
Trial primary completion date: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause (clinicaltrials.gov) - Feb 1, 2023
P2a, N=56, Recruiting, Sponsor: Acer Therapeutics Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2022 --> Mar 2023
- | Edsivo (celiprolol) / Acer Therap
Journal: Vascular Involvements Are Common in the Branch Arteries of the Abdominal Aorta Rather Than in the Aorta in Vascular Ehlers-Danlos Syndrome. (Pubmed Central) - Jan 27, 2023
Of the 20 patients, 17 took celiprolol at final assessment...During follow-up, 3 patients died due to suspected ruptures in a branch of the celiac artery, the superior mesenteric artery, and the aorta. Our findings indicate that lesions involving the branch arteries of the abdominal aorta, rather than aorta, were the most prevalent lesion type in patients with vEDS.
- | osanetant (ACER-801) / Sanofi, Acer Therap
Enrollment open: PORT-MAP: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (clinicaltrials.gov) - Jan 5, 2023
P1, N=10, Recruiting, Sponsor: University of Kansas Medical Center
Our findings indicate that lesions involving the branch arteries of the abdominal aorta, rather than aorta, were the most prevalent lesion type in patients with vEDS. Not yet recruiting --> Recruiting
- | Edsivo (celiprolol) / Acer Therap, Visken (pindolol) / Novartis, bevantolol (SOM3355) / SOM Biotech
Journal: β-arrestin2 recruitment by β-adrenergic receptor agonists and antagonists (Pubmed Central) - Jan 4, 2023
β2-AR selective antagonists butoxamine showed β-arrestin2 recruitment at β1-AR. These results provide some clues for the potential action of β-AR drugs, and lay a foundation for the screening of β-arrestin-biased β-AR ligands.
- | osanetant (ACER-801) / Sanofi, Zevra Therap
Enrollment open: POSH-MAP: Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate (clinicaltrials.gov) - Jan 4, 2023
P1, N=10, Recruiting, Sponsor: University of Kansas Medical Center
These results provide some clues for the potential action of β-AR drugs, and lay a foundation for the screening of β-arrestin-biased β-AR ligands. Not yet recruiting --> Recruiting
- | osanetant (ACER-801) / Sanofi, Zevra Therap
New P1 trial: POSH-MAP: Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate (clinicaltrials.gov) - Dec 12, 2022
P1, N=10, Not yet recruiting, Sponsor: University of Kansas Medical Center
- |||| Edsivo (celiprolol) / Acer Therap
Trial initiation date: DiSCOVER: Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Nov 10, 2022
P3, N=150, Recruiting, Sponsor: Acer Therapeutics Inc.
Not yet recruiting --> Recruiting Initiation date: Jun 2022 --> Nov 2022
- | osanetant (ACER-801) / Sanofi, Acer Therap
New P1 trial: PORT-MAP: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (clinicaltrials.gov) - Nov 7, 2022
P1, N=10, Not yet recruiting, Sponsor: University of Kansas Medical Center
- | Edsivo (celiprolol) / Acer Therap
Journal: Vascular Ehlers Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches. (Pubmed Central) - Oct 12, 2022
Mice with vEDS traits treated with a beta-blocker celiprolol showed significant improvements in their thoracic aorta biomechanical strength...Similarly, an embryonic homeobox transcription factor Nanog upregulates the wild-type COL3A1 expression through activation of the transforming growth factor-beta pathway, which increases type III collagen synthesis. Despite numerous advancements, more studies are to be performed to incorporate these discoveries into clinical settings, and eventually, more personalized treatments can be created.
- || Edsivo (celiprolol) / Acer Therap, Invirase (saquinavir) / Roche, Crixivan (indinavir sulfate) / Merck (MSD)
Review, Journal: Phytochemicals That Interfere With Drug Metabolism and Transport, Modifying Plasma Concentration in Humans and Animals. (Pubmed Central) - Sep 29, 2022
Interactions between Pchs and drugs affect the gene expression and enzymatic activity of CYP3A and P-gp transporter, which has an impact on their bioavailability; such that co-administration of drugs with food, beverages and food supplements can cause a subtherapeutic effect or overdose. Therefore, it is important for the clinician to consider these interactions to obtain a better therapeutic effect.
- ||| Edsivo (celiprolol) / Acer Therap
Enrollment status: DiSCOVER: Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Sep 15, 2022
P3, N=150, Recruiting, Sponsor: Acer Therapeutics Inc.
Therefore, it is important for the clinician to consider these interactions to obtain a better therapeutic effect. Enrolling by invitation --> Recruiting
- || osanetant (ACER-801) / Sanofi, Acer Therap
Enrollment status, Trial completion date, Trial primary completion date: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause (clinicaltrials.gov) - Sep 15, 2022
P2a, N=56, Recruiting, Sponsor: Acer Therapeutics Inc.
Enrolling by invitation --> Recruiting Enrolling by invitation --> Recruiting | Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Aug 2022 --> Dec 2022
- ||| Edsivo (celiprolol) / Acer Therap
Enrollment status: DiSCOVER: Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Aug 15, 2022
P3, N=150, Enrolling by invitation, Sponsor: Acer Therapeutics Inc.
Enrolling by invitation --> Recruiting | Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Aug 2022 --> Dec 2022 Recruiting --> Enrolling by invitation
- || osanetant (ACER-801) / Sanofi, Acer Therap
Enrollment status: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause (clinicaltrials.gov) - Jul 18, 2022
P2a, N=56, Enrolling by invitation, Sponsor: Acer Therapeutics Inc.
Recruiting --> Enrolling by invitation Recruiting --> Enrolling by invitation
- |||| Edsivo (celiprolol) / Acer Therap
Enrollment open: DiSCOVER: Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Jun 28, 2022
P3, N=150, Recruiting, Sponsor: Acer Therapeutics Inc.
Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- |||||||| Edsivo (celiprolol) / Acer Therap
New P3 trial: DiSCOVER: Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Jun 27, 2022
P3, N=150, Not yet recruiting, Sponsor: Acer Therapeutics Inc.
- | osanetant (ACER-801) / Sanofi, Acer Therap
Trial completion date: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause (clinicaltrials.gov) - Jun 22, 2022
P2a, N=56, Recruiting, Sponsor: Acer Therapeutics Inc.
Not yet recruiting --> Recruiting Trial completion date: Dec 2022 --> Sep 2022
- | osanetant (SR 142801) / Sanofi, Acer Therap
Preclinical, Journal: Nk3R blockade has sex-divergent effects on memory in mice. (Pubmed Central) - Jun 20, 2022
Trial completion date: Dec 2022 --> Sep 2022 These data propose novel ideas on functional interactions between Nk3R, sex hormones, estrogen receptors, and androgen receptors in memory consolidation.
- | osanetant (ACER-801) / Sanofi, Acer Therap
New P2a trial: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause (clinicaltrials.gov) - Apr 13, 2022
P2a, N=56, Recruiting, Sponsor: Acer Therapeutics Inc.
- SRX246 / Azevan, osanetant (SR 142801) / Sanofi, Acer Therap
Chair (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_6814;
Finally, we will present data from human subjects showing that highly selective vasopressin 1A receptor antagonist SRX246 reduces anxiety but not fear-potentiated startle in male and female participants. This mini-symposium will address sex-specific effects of limbic neuropeptides in both rodents and humans and the importance of sex-specific pharmacotherapies for PTSD.
- SRX246 / Azevan, osanetant (SR 142801) / Sanofi, Acer Therap
The role of Angiotensin II in Fear Memory and therapeutic opportunities for PTSD (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_6803;
Finally, we will present data from human subjects showing that highly selective vasopressin 1A receptor antagonist SRX246 reduces anxiety but not fear-potentiated startle in male and female participants. This mini-symposium will address sex-specific effects of limbic neuropeptides in both rodents and humans and the importance of sex-specific pharmacotherapies for PTSD.
- SRX246 / Azevan, osanetant (SR 142801) / Sanofi, Acer Therap
Clinical translation of oxytocin neuroscience to the treatment of anxiety and posttraumatic stress disorders (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_6802;
Finally, we will present data from human subjects showing that highly selective vasopressin 1A receptor antagonist SRX246 reduces anxiety but not fear-potentiated startle in male and female participants. This mini-symposium will address sex-specific effects of limbic neuropeptides in both rodents and humans and the importance of sex-specific pharmacotherapies for PTSD.
- SRX246 / Azevan, osanetant (SR 142801) / Sanofi, Acer Therap
Oxytocin facilitates fear memory to predictable threats by inhibiting output neurons of the bed nucleus of the stria terminalis (BNST). (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_6801;
Finally, we will present data from human subjects showing that highly selective vasopressin 1A receptor antagonist SRX246 reduces anxiety but not fear-potentiated startle in male and female participants. This mini-symposium will address sex-specific effects of limbic neuropeptides in both rodents and humans and the importance of sex-specific pharmacotherapies for PTSD.
- SRX246 / Azevan, osanetant (SR 142801) / Sanofi, Acer Therap
Sex-opposite effects of the neurokinin 3 receptor neuropeptide in memory consolidation (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_6800;
Finally, we will present data from human subjects showing that highly selective vasopressin 1A receptor antagonist SRX246 reduces anxiety but not fear-potentiated startle in male and female participants. This mini-symposium will address sex-specific effects of limbic neuropeptides in both rodents and humans and the importance of sex-specific pharmacotherapies for PTSD.
- SRX246 / Azevan, osanetant (SR 142801) / Sanofi, Acer Therap
Stress-enhanced fear learning, violence, and the neuropeptide Tac2 (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_6799;
Finally, we will present data from human subjects showing that highly selective vasopressin 1A receptor antagonist SRX246 reduces anxiety but not fear-potentiated startle in male and female participants. This mini-symposium will address sex-specific effects of limbic neuropeptides in both rodents and humans and the importance of sex-specific pharmacotherapies for PTSD.
- SRX246 / Azevan, osanetant (SR 142801) / Sanofi, Acer Therap
Co Chair (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_6798;
Finally, we will present data from human subjects showing that highly selective vasopressin 1A receptor antagonist SRX246 reduces anxiety but not fear-potentiated startle in male and female participants. This mini-symposium will address sex-specific effects of limbic neuropeptides in both rodents and humans and the importance of sex-specific pharmacotherapies for PTSD.
- SRX246 / Azevan, osanetant (SR 142801) / Sanofi, Acer Therap
Chair (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_6797;
Finally, we will present data from human subjects showing that highly selective vasopressin 1A receptor antagonist SRX246 reduces anxiety but not fear-potentiated startle in male and female participants. This mini-symposium will address sex-specific effects of limbic neuropeptides in both rodents and humans and the importance of sex-specific pharmacotherapies for PTSD.
- || osanetant (SR 142801) / Sanofi, Acer Therap
4) The research team had identified that the Tac2 circuit, located in the amygdala, could be temporarily blocked by the effect of a drug they are studying. This drug is called Osanetant. (Twitter) - May 8, 2021
- osanetant (SR 142801) / Sanofi, Acer Therap
[VIRTUAL] Modeling shows the NK3R antagonist, ACER-801, reduces treatment-induced vasomotor symptoms. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3706;
Simulations show ACER-801 may be highly efficacious for the treatment of induced-VMS . The research provided estimates of DDI with ACER-801 and tamoxifen and what clinical experiments would be needed to confirm those estimates.
- | Edsivo (celiprolol) / Acer Therap
Trial completion, Trial completion date, Trial primary completion date: CPET1: Chronic Beta-blockade and Cardiopulmonary Exercise in COPD (clinicaltrials.gov) - Jun 24, 2019
P4, N=10, Completed, Sponsor: University of Dundee
The research provided estimates of DDI with ACER-801 and tamoxifen and what clinical experiments would be needed to confirm those estimates. Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Apr 2019 | Trial primary completion date: Aug 2019 --> Apr 2019
- | Edsivo (celiprolol) / Acer Therap
Enrollment closed: CPET1: Chronic Beta-blockade and Cardiopulmonary Exercise in COPD (clinicaltrials.gov) - Mar 27, 2019
P4, N=10, Active, not recruiting, Sponsor: University of Dundee
Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Apr 2019 | Trial primary completion date: Aug 2019 --> Apr 2019 Recruiting --> Active, not recruiting
- | Edsivo (celiprolol) / Acer Therap
New P2 trial, Surgery: CelDilPreCA: Celiprolol Versus Ditiazem for the Prevention of Postoperative Cardiac Arrythmias in Thoracic Surgery (clinicaltrials.gov) - Nov 26, 2018
P2, N=30, Not yet recruiting, Sponsor: Abderrahmane Mami Hospital
- | Edsivo (celiprolol) / Acer Therap
Trial completion date, Trial primary completion date: CPET1: Chronic Beta-blockade and Cardiopulmonary Exercise in COPD (clinicaltrials.gov) - Sep 17, 2018
P4, N=10, Recruiting, Sponsor: University of Dundee
Recruiting --> Active, not recruiting Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Edsivo (celiprolol) / Acer Therap
Trial primary completion date: CPET1: Chronic Beta-blockade and Cardiopulmonary Exercise in COPD (clinicaltrials.gov) - Nov 6, 2017
P4, N=10, Recruiting, Sponsor: University of Dundee
Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial primary completion date: Jun 2017 --> Aug 2018
- |||| Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
Trial completion: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jan 10, 2017
P2, N=183, Completed, Sponsor: Opexa Therapeutics, Inc.
Trial primary completion date: Jun 2017 --> Aug 2018 Active, not recruiting --> Completed
- Edsivo (celiprolol) / Acer Therap
Enrollment open, Trial initiation date, Trial primary completion date: CPET1: Chronic Beta-blockade and Cardiopulmonary Exercise in COPD (clinicaltrials.gov) - Jun 11, 2016
P4, N=10, Recruiting, Sponsor: University of Dundee
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Jun 2016 | Trial primary completion date: Apr 2016 --> Jun 2017
- Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
Trial primary completion date: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jul 9, 2015
P2, N=180, Active, not recruiting, Sponsor: Opexa Therapeutics, Inc.
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Jun 2016 | Trial primary completion date: Apr 2016 --> Jun 2017 Trial primary completion date: Dec 2015 --> Aug 2016
- Edsivo (celiprolol) / Acer Therap
New P4 trial: CPET1: Chronic Beta-blockade and Cardiopulmonary Exercise in COPD (clinicaltrials.gov) - Mar 7, 2015
P4, N=10, Not yet recruiting, Sponsor: University of Dundee
- ||| Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
Enrollment closed: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jun 19, 2014
P2, N=180, Active, not recruiting, Sponsor: Opexa Therapeutics, Inc.
Trial primary completion date: Dec 2015 --> Aug 2016 Recruiting --> Active, not recruiting
- ||||| Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
New P2 trial: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Sep 11, 2012
P2, N=180, Recruiting, Sponsor: Opexa Therapeutics, Inc.